BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22869377)

  • 1. High immunogenicity of the human leukocyte antigen peptidomes of melanoma tumor cells.
    Jarmalavicius S; Welte Y; Walden P
    J Biol Chem; 2012 Sep; 287(40):33401-11. PubMed ID: 22869377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
    Gloger A; Ritz D; Fugmann T; Neri D
    Cancer Immunol Immunother; 2016 Nov; 65(11):1377-1393. PubMed ID: 27600516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.
    Bassani-Sternberg M; Pletscher-Frankild S; Jensen LJ; Mann M
    Mol Cell Proteomics; 2015 Mar; 14(3):658-73. PubMed ID: 25576301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
    Murata K; Nakatsugawa M; Rahman MA; Nguyen LT; Millar DG; Mulder DT; Sugata K; Saijo H; Matsunaga Y; Kagoya Y; Guo T; Anczurowski M; Wang CH; Burt BD; Ly D; Saso K; Easson A; Goldstein DP; Reedijk M; Ghazarian D; Pugh TJ; Butler MO; Mak TW; Ohashi PS; Hirano N
    Elife; 2020 Apr; 9():. PubMed ID: 32314731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
    Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
    Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
    Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
    Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficiency and mechanism of antigen-specific CD8+ T-cell activation using synthetic long peptides.
    Zandvliet ML; Kester MG; van Liempt E; de Ru AH; van Veelen PA; Griffioen M; Guchelaar HJ; Falkenburg JH; Meij P
    J Immunother; 2012; 35(2):142-53. PubMed ID: 22306902
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Schmidt J; Guillaume P; Dojcinovic D; Karbach J; Coukos G; Luescher I
    J Biol Chem; 2017 Jul; 292(28):11840-11849. PubMed ID: 28536262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential arginine methylation of the G-protein pathway suppressor GPS-2 recognized by tumor-specific T cells in melanoma.
    Jarmalavicius S; Trefzer U; Walden P
    FASEB J; 2010 Mar; 24(3):937-46. PubMed ID: 19917673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method.
    Flad T; Spengler B; Kalbacher H; Brossart P; Baier D; Kaufmann R; Bold P; Metzger S; Blüggel M; Meyer HE; Kurz B; Müller CA
    Cancer Res; 1998 Dec; 58(24):5803-11. PubMed ID: 9865739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequence conservation analysis and in silico human leukocyte antigen-peptide binding predictions for the Mtb72F and M72 tuberculosis candidate vaccine antigens.
    Mortier MC; Jongert E; Mettens P; Ruelle JL
    BMC Immunol; 2015 Oct; 16():63. PubMed ID: 26493839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.
    Parkhurst MR; DePan C; Riley JP; Rosenberg SA; Shu S
    J Immunol; 2003 May; 170(10):5317-25. PubMed ID: 12734382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.
    Skipper JC; Gulden PH; Hendrickson RC; Harthun N; Caldwell JA; Shabanowitz J; Engelhard VH; Hunt DF; Slingluff CL
    Int J Cancer; 1999 Aug; 82(5):669-77. PubMed ID: 10417764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens.
    Khazan-Kost S; Cafri G; Melamed Kadosh D; Mooshayef N; Chatterji S; Dominissini D; Manor S; Zisser B; Broday L; Talalai E; Shemer A; Zadok O; Ofek E; Onn A; Admon A; Peled M
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing the spontaneous modification of an HLA-A2-restricted peptide at an N-terminal glutamine or an internal cysteine residue enhances peptide antigenicity.
    Thompson LW; Hogan KT; Caldwell JA; Pierce RA; Hendrickson RC; Deacon DH; Settlage RE; Brinckerhoff LH; Engelhard VH; Shabanowitz J; Hunt DF; Slingluff CL
    J Immunother; 2004; 27(3):177-83. PubMed ID: 15076134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis.
    Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
    J Immunol Methods; 2000 Oct; 244(1-2):59-67. PubMed ID: 11033019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.
    Benlalam H; Linard B; Guilloux Y; Moreau-Aubry A; Derré L; Diez E; Dreno B; Jotereau F; Labarrière N
    J Immunol; 2003 Dec; 171(11):6283-9. PubMed ID: 14634146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
    Riley JP; Rosenberg SA; Parkhurst MR
    J Immunol Methods; 2003 May; 276(1-2):103-19. PubMed ID: 12738363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of melanoma-specific peptide epitopes by HLA-A2.1-restricted cytotoxic T lymphocytes.
    Ge HL; Wang Y; Wang SJ; Zhang Y
    Acta Biochim Biophys Sin (Shanghai); 2006 Feb; 38(2):110-8. PubMed ID: 16474902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.